We are live on ! Find out more
RETA

Reata Pharmaceuticals, Inc. Class A Common Stock
RETA

Delisted

RETA was delisted on the 25th of September, 2023.

Back to rankings

2 hedge funds and large institutions have $2.98M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 210 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% less call options, than puts

Call options by funds: $16.5M | Put options by funds: $50.7M

99% less funds holding

Funds holding: 214 → 2 (-212)

100% less capital invested

Capital invested by funds: $3.21B → $2.98M (-$3.21B)

100% less funds holding in top 10

Funds holding in top 10: 8 → 0 (-8)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 210

Holders
2
Holders Change
-212
Holders Change %
-99.07%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
210
Calls
$16.5M
Puts
$50.7M
Net Calls
-$34.3M
Net Calls Change
-$53.4M

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CI
CPMG Inc
Texas
-$295M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$288M
3
BlackRock
BlackRock
New York
-$259M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$180M
5
Deutsche Bank
Deutsche Bank
Germany
-$152M
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$2.93M – – –
IA
2
IFP Advisors
Florida
$51.7K – – –
CI
3
CPMG Inc
Texas
– -$295M -2,896,901 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$288M -2,821,537 Closed
BlackRock
5
BlackRock
New York
– -$259M -2,538,770 Closed
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
– -$180M -1,766,070 Closed
Deutsche Bank
7
Deutsche Bank
Germany
– -$152M -1,486,467 Closed
Wellington Management Group
8
Wellington Management Group
Massachusetts
– -$150M -1,472,043 Closed
FLAM
9
First Light Asset Management
Minnesota
– -$146M -1,432,208 Closed
BC
10
Boxer Capital
California
– -$146M -1,430,004 Closed
Janus Henderson Group
11
Janus Henderson Group
United Kingdom
– -$107M -1,051,077 Closed
State Street
12
State Street
Massachusetts
– -$72.7M -713,150 Closed
PA
13
Perceptive Advisors
New York
– -$68.3M -670,206 Closed
Holocene Advisors
14
Holocene Advisors
New York
– -$68.1M -667,950 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$60.5M -593,430 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$58.3M -571,529 Closed
Point72 Asset Management
17
Point72 Asset Management
Connecticut
– -$57.9M -568,151 Closed
Millennium Management
18
Millennium Management
New York
– -$56.7M -556,264 Closed
FCM
19
Farallon Capital Management
California
– -$46.1M -451,700 Closed
FAM
20
Fred Alger Management
New York
– -$41.5M -407,170 Closed
TCM
21
TimesSquare Capital Management
New York
– -$35.1M -344,580 Closed
Blackstone Inc
22
Blackstone Inc
New York
– -$34.7M -340,793 Closed
Invesco
23
Invesco
Georgia
– -$34.7M -340,654 Closed
VOYA Investment Management
24
VOYA Investment Management
Georgia
– -$33.6M -329,189 Closed
SI
25
Sofinnova Investments
California
– -$32.9M -322,471 Closed
1
2 3 4 5

RETA Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2023, worth a combined $2.98M — down 100% from $3.21B a quarter earlier.

Sellers outnumbered buyers: 210 funds closed out of RETA and 0 opened new positions — a net loss of 210 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was CPMG Inc, exiting entirely with an estimated $295M sold.

  • 2 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2023, down from 214 in Q2 2023.
  • Funds reported $2.98M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2023 and 210 closed out, a net change of -210 holders.
  • The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2023 was CPMG Inc, an estimated $295M sold.

Based on aggregated 13F filings for Q3 2023.